Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.
Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C. Varnier R, et al. Among authors: tredan o. Front Oncol. 2021 Sep 24;11:756365. doi: 10.3389/fonc.2021.756365. eCollection 2021. Front Oncol. 2021. PMID: 34631593 Free PMC article.
Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings.
Hequet D, Hajjaji N, Charafe-Jauffret E, Boucrauta A, Dalenc F, Nicolai V, Lopez J, Tredan O, Deluche E, Fermeaux V, Tixier L, Cayre A, Menet E, Lerebours F, Rouzier R. Hequet D, et al. Among authors: tredan o. Cancer Med. 2023 Aug;12(16):16889-16895. doi: 10.1002/cam4.6315. Epub 2023 Jul 6. Cancer Med. 2023. PMID: 37409516 Free PMC article.
Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
Zenatri M, Perennec T, Michon C, Gernier F, Grellard JM, Piloquet FX, Dubot-Poitelon C, Kalbacher E, Tredan O, Augereau P, Pautier P, Fey L, Joly F, Frenel JS. Zenatri M, et al. Among authors: tredan o. Gynecol Oncol. 2024 May 21;187:139-144. doi: 10.1016/j.ygyno.2024.04.021. Online ahead of print. Gynecol Oncol. 2024. PMID: 38776631
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
Goetz MP, Toi M, Huober J, Sohn J, Trédan O, Park IH, Campone M, Chen SC, Manso LM, Paluch-Shimon S, Freedman OC, O'Shaughnessy J, Pivot X, Tolaney SM, Hurvitz S, Llombart-Cussac A, André V, Saha A, van Hal G, Shahir A, Iwata H, Johnston SRD. Goetz MP, et al. Among authors: tredan o. Ann Oncol. 2024 May 8:S0923-7534(24)00139-X. doi: 10.1016/j.annonc.2024.04.013. Online ahead of print. Ann Oncol. 2024. PMID: 38729566 Free article.
Added value of whole-exome and RNA sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel.
Dufresne A, Attignon V, Ferrari A, Tonon L, Boyault S, Tabone-Eglinger S, Cassier P, Trédan O, Corradini N, Vinceneux A, Swalduz A, Viari A, Chabaud S, Pérol D, Blay JY, Saintigny P. Dufresne A, et al. Among authors: tredan o. Cancer Med. 2024 Apr;13(7):e7115. doi: 10.1002/cam4.7115. Cancer Med. 2024. PMID: 38553950 Free PMC article.
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M. Freyer G, et al. Among authors: tredan o. Nat Commun. 2024 Mar 5;15(1):1985. doi: 10.1038/s41467-024-45974-w. Nat Commun. 2024. PMID: 38443333 Free PMC article. Clinical Trial.
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes.
Franzoi MA, Aupomerol M, Havas J, Soldato D, Lambertini M, Massarotti C, Hang H, Pistilli B, Fasse L, Tredan O, Gillanders E, Joly F, Cottu P, Mouret-Reynier MA, Tarpin C, Arnaud A, Everhard S, Martin AL, Di Meglio A, Vaz-Luis I. Franzoi MA, et al. Among authors: tredan o. ESMO Open. 2024 Feb;9(2):102236. doi: 10.1016/j.esmoop.2024.102236. Epub 2024 Feb 12. ESMO Open. 2024. PMID: 38350335 Free PMC article.
Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023.
Gligorov J, Benderra MA, Barthere X, de Forceville L, Antoine EC, Cottu PH, Delaloge S, Pierga JY, Belkacemi Y, Houvenaegel G, Pujol P, Rivera S, Spielmann M, Penault-Llorca F, Namer M; et l'ensemble des experts des votes des RPC Saint-Paul 2022-2023. Gligorov J, et al. Bull Cancer. 2023 Nov;110(10S):10S1-10S43. doi: 10.1016/S0007-4551(23)00473-3. Bull Cancer. 2023. PMID: 38061827
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.
Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. Lambertini M, et al. JAMA. 2024 Jan 2;331(1):49-59. doi: 10.1001/jama.2023.25463. JAMA. 2024. PMID: 38059899
209 results